Engchanil Chulapan, Kosalaraksa Pope, Lumbiganon Pagakrong, Lulitanond Viraphong, Pongjunyakul Piyaporn, Thuennadee Ruengsin, Tungsawad Sasithorn, Suwan-apichon Olan
Department of Microbiology, Faculty of Medicine, Khon Kaen University, Thailand.
J Med Assoc Thai. 2006 Aug;89(8):1229-36.
To evaluate the efficacy and safety of CHQ in a combination treatment with ZDV/ddI in HIV-1-infected children.
Fifty five HIV-infected children were randomly enrolled into 3 treatment groups: (I) ZDV + ddI (n = 25); and (II) ZDV + ddI + CHQ (n = 21); and (III) ZDV + ddI experienced children were non-randomly added CHQ (n = 9). Weight, CD4+ T-lymphocytes and plasma HIV-RNA were measured at weeks 0, 8 and 24.
Fifteen, 16 and 8 children from Groups I, II and III were evaluated. No significant improvement in the mean Z-score for weight in groups I and II, but a decrease occurred in group III after 6 months of therapy. In group I, II and III, the respective change in the mean CD4+ T-lymphocyte percentage was +6.7, +4.0 and -0.6. The decrease in the plasma HIV-RNA log was 0.9, 1.1 and 0.7, respectively. There was a trend for more nausea/vomiting in group II/III and more opportunistic infections in group III.
评估氯喹（CHQ）与齐多夫定（ZDV）/双脱氧肌苷（ddI）联合治疗对HIV-1感染儿童的疗效和安全性。
55名HIV感染儿童被随机分为3个治疗组：（I）ZDV + ddI组（n = 25）；（II）ZDV + ddI + CHQ组（n = 21）；（III）曾接受ZDV + ddI治疗的儿童非随机加用CHQ组（n = 9）。在第0、8和24周测量体重、CD4 + T淋巴细胞和血浆HIV-RNA。
对I、II和III组分别有15、16和8名儿童进行了评估。I组和II组体重的平均Z评分无显著改善，但III组在治疗6个月后出现下降。在I组、II组和III组中，CD4 + T淋巴细胞百分比的平均变化分别为+6.7、+4.0和-0.6。血浆HIV-RNA对数下降分别为0.9、1.1和0.7。II/III组恶心/呕吐较多，III组机会性感染较多，存在这种趋势。
